Bibliography
- Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population. The Rotterdam study. Arch Ophthalmol 1998;116:653-8
- Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol1996;80:389-93
- Carter CJ, Brooks DE, Doyle DL, Drance SM. Investigation into a vascular aetiology for low tension glaucoma. Ophthalmology1990;97:49-55
- Hayreh SS. Progress in the understanding of the vascular aetiology of glaucoma. Curr Opin Ophthalmol1994;5:26-35
- Flammer J, Orgül S, Costa VP, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res2002;21:359-93
- Galassi F, Sodi A, Ucci F, et al. Ocular hemodynamics and glaucoma prognosis: a color doppler imaging study. Arch Ophthalmol2003;121:1711-15
- Satilmis M, Orgul S, Doubler B, Flammer J. Rate of progression of glaucoma correlates with retrobulbar circulation and intraocular pressure. Am J Ophthalmol2003;135:664-9
- Martinez A, Sanchez M. Predictive value of color doppler imaging in a prospective study of visual field progression in primary open-angle glaucoma. Acta Ophthalmol Scand2005;83:716-23
- Zeitz O, Galambos P, Weirmann A, et al. Glaucoma progression is associated with decreased blood flow velocities in the short posterior ciliary artery. Br J Ophthalmol2006;90:1245-8
- European Glaucoma Society. Terminology and Guidelines for Glaucoma 2nd Edition. DOGMA S.r.l. Savona – Italy, 2003
- Patel SC, Spaeth GL. Compliance in patients prescribed eye-drops for glaucoma. Ophthal Surg1995;26:233-6
- Weinreb RN. Compliance with medical treatments in glaucoma. J Glaucoma1992;1:134-6
- Cantor LB. Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Expert Opin Investig Drugs2001;10:721-31
- Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol2001;45(Suppl.):S337-45
- Woodward DF, Krauss AH, Wang JW, et al. Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris. Br J Pharmacol2007;150(3):342-52
- Liang Y, Chen L, Guzman VM, et al. Identification of alternative splices of human prostaglandin FP receptor mRNA. FASEB2005; Abstr 639.4
- Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging2002;19(3):231-48
- Christiansen GA, Nau CB, McLaren JW, et al. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology2004;111(9):1658-62
- Chen J, Dinhn T, Woodward DF, et al. Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy. Cardivasc Drug Rev2005;23(3):231-46
- Kiland JA, Gabelt BT, Kaufman PL. Studies on the mechanism of action of timolol and on effects of suppression and redirection of aqueous flow on outflow facility. Exp Eye Res2004;78(3):639-51
- Nieminen T, Uusilato H, Maenpaa J, et al. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol2005;61(11):626-32
- Committee for Medical Products for Human Use (CHMP). Scientific discussion (of Ganfort) [on line]. Available from URL: http//www.emea.eu.int/humandocs/Humans/EPAR/ganfort/ganfort.htm (Accessed 28 September 2006)
- Katz LJ, Lewis RA, Batoosingh AL, Liu C; for the Ganfort® Investigators' Group II. Bimatoprost/Timolol Fixed Combination: A one-year, double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. Poster presentation ARVO, Fort Lauderdal, Mayo 2007
- Brandt JD, Cantor LB, Batoosingh AL, Liu C; for the Ganfort® Investigators' Group. A 3-month, randomized study comparing bimatoprost/timolol fixed-combination therapy to monotherapy with bimatoprost or timolol in patients with glaucoma or ocular hypertension. Poster presentation IGS, Athens, April 2007
- Hommer A; Ganfort investigators group I. A double-masked, randimized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol2007;17(1):53-62
- Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering effect of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin2007;23(5):1025-32